Abstract:1549 Objectives: Molecular imaging of tauopathies is complicated by the differing specificities and off-target binding properties of available ligands for positron-emission-tomography (PET). [18F]-APN-1607 ([18F]-PM-PBB3) is a newly developed tau tracer. The aim of the study was to characterize the imaging properties of [18F]-APN-1607 in Alzheimer’s disease (AD) patients compared to normal control (NC) subjects.\n Methods: We obtained PET recordings with [18F]-APN-1607 and [18F]-FDG in patients with a clinical diagnosis of AD group (N=19, 61.83±11.89 y,7 male/12 female), along with an age-matched NC group ([18F]-APN-1607 only, N=11, 61.79±4.64 y, 7 male/4 female). Meanwhile, all subjects underwent anatomical magnetic resonance imaging (MRI) within one month. The tosylate precursor used for the synthesis of [18F]-APN-1607 was provided by APRINOIA Therapeutics (Suzhou, China) and the synthesis was prepared in Huashan hospital (Shanghai, China). Using statistical parametric mapping (SPM) and volume of interest (VOI) (PMOD Version 4.005 (PMOD Technologies Ltd., Zurich, Switzerland)) analyses of the reference region normalized standard uptake value (SUV) maps, we then tested for group differences and relationships between two modes of PET as well as clinical general cognition.\n Results: We found that, for the AD group, [18F]-APN-1607 binding was elevated in widespread cortical regions (Figure1) (P\u003c0.001 for VOI analysis(Figure2), family wise error-corrected P\u003c0.01 for SPM analysis(Figure3)) and correlated negatively with mini-mental state examination (MMSE) score (frontal lobe: R=-0.632, P=0.004; temporal lobe: R=-0.593, P=0.008; parietal lobe: R=-0.552, P=0.014; insula: R=-0.650, P=0.003; cingulum: R=-0.665, P=0.002) except occipital lobe (R=-0.417, P=0.076). The hypometabolism in signature areas of AD also showed correlations with regional [18F]-APN-1607 bindings (frontal lobe: R=-0.421, P=0.073; temporal lobe: R=-0.530, P=0.020; parietal lobe: R=-0.637, P=0.003).\n Conclusions: Our results suggest that [18F]-APN-1607 detects tau deposition in AD effectively, correlating with metabolism and cognitive function.

Synthesis and Preclinical Evaluation of 2-(4-[18f]fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([18F]FPND-4): an Aza-Fused Tricyclic Derivative As Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging.

Synthesis and Preclinical Evaluation of 2-(4-[ 18 F]Fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([ 18 F]FPND-4): An Aza-Fused Tricyclic Derivative as Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging

Synthesis and Bioevaluation of 2-Styrylquinoxaline Derivatives As Tau-PET Tracers.

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

Synthesis and Preclinical Evaluation of Diarylamine Derivative As Tau-PET Radiotracer for Alzheimer’s Disease

Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives As Potential Tau Imaging Agents.

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease

Improved Preparation and Chemical Kinetics on Fully Automated Synthesis of [ 18 F]-THK523, a PET Imaging Probe for Tau Pathologies

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Biological Characteristics of [ 18 F]-THK523 for Tau Imaging

Novel 18F-Labeled Benzoxazole Derivatives As Potential Positron Emission Tomography Probes for Imaging of Cerebral Β-Amyloid Plaques in Alzheimer’s Disease

Novel 18F-Labeled Benzofuran Derivatives with Improved Properties for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques in Alzheimer’s Brains

Synthesis and Evaluation of Novel ¹⁸F Labeled 2-Pyridinylbenzoxazole and 2-Pyridinylbenzothiazole Derivatives As Ligands for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques.

Optimization and Biodistribution of [11C]-TKF, an Analog of Tau Protein Imaging Agent [18F]-THK523

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

Recent Development in Selective Tau Tracers for PET Imaging in the Brain

Discovery and evaluation of aza-fused tricyclic derivatives for detection of Tau pathology in Alzheimer's disease

Synthesis and Bioevaluation of Technetium-99 M / Rhenium Labeled Phenylquinoxaline Derivatives As Tau Imaging Probes.

Synthesis and Biological Evaluation of 18F-Labled 2-Phenylindole Derivatives As PET Imaging Probes for Β-Amyloid Plaques

Synthesis and Radiolabelling of A Radiofluorinated Pet Imaging Probe Based on Pib and Thk523

Syntheses and Evaluation of Fluorinated Benzothiazole Anilines As Potential Tracers for Β-Amyloid Plaques in Alzheimer's Disease